Plasma immune proteome-based risk score predicts survival in advanced gastric cancer treated with PD-1 inhibitors and chemotherapy.

ABSTRACT:

Background

Blood-based biomarkers that capture systemic immunity could complement tissue-based assays for prognostication in advanced gastric cancer receiving programmed cell death protein 1 (PD-1)-based chemoimmunotherapy. We evaluated whether baseline plasma immune proteomics can stratify clinical outcomes and be operationalized into a clinically usable model.

Methods

In a prospective cohort (n=40) treated with first-line PD-1 inhibitor plus chemotherapy, nano-ultra-high-performance liquid chromatography (nano-UHPLC) coupled with Orbitrap data-independent acquisition liquid chromatography-tandem mass spectrometry (DIA LC-MS/MS) was used to profile baseline plasma. Quality control (QC)-filtered protein intensities were median-normalized, log₂-transformed, and bat

SUBMITTER: Zhan Z 

PROVIDER: S-EPMC12832679 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature